FIELD: pharmacology.
SUBSTANCE: suggested: 2-methylphenoxyacetate N-methyl-bis-(2-hydroxyethyl)ammonium (Bikrezan) of the formula [CH3N(CH2CH2OH)2H]+⋅-OOCCH2OC6H4-CH3-2 application as an antineoplastic and antimetastatic means. Technical result: the antitumor effect of Bikrezan is shown in vivo on an example of melanoma and hepatoma; the antimetastatic effect of Bikrezan exceeds the cisplatin effect, while Bikrezan is safe - it has no toxic properties.
EFFECT: invention expands the arsenal of funds for the intended purpose, exceeding the therapeutic effect of other anti-cancer drugs.
4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-TUMOR AGENT | 2003 |
|
RU2240793C1 |
ANTITUMOR AGENT | 2003 |
|
RU2253446C1 |
METHOD OF PRODUCING 2-METHYL-4-HALOGEN-PHENOXYACETATES OF TRIS-(2-HYDROXYETHYL)AMMONIUM (2-METHYL-4-HALOGEN-PHENOXYACETOXYPROTATRANES) | 2009 |
|
RU2427568C2 |
METHOD OF COMBINATION THERAPY OF B16 MELANOMA IN METRONOMIC MODE IN EXPERIMENT | 2022 |
|
RU2792561C1 |
PHARMACEUTICAL COMPOSITION BASED ON PALLADIUM COMPOUND | 2015 |
|
RU2613305C2 |
METHOD FOR OBTAINING OF 1-R-INDOLE-3-YLSULFANYLACETATES OF (2-HYDROXYETHYL)AMMONIUM | 2016 |
|
RU2642778C2 |
METHOD FOR ACHIEVING ANTIMETASTATIC EFFECT IN EXPERIMENT | 2017 |
|
RU2661704C1 |
ANGIOGENESIS INHIBITOR, ANTI-ANGIOGENIC PHARMACEUTICAL COMPOSITION BASED ON THEREOF AND METHOD FOR TREATMENT OF MALIGNANT NEOPLASM | 2005 |
|
RU2287341C1 |
ANTICANCER AGENT | 2011 |
|
RU2455011C1 |
ANTIMETASTATIC COMPOSITION | 2006 |
|
RU2308966C1 |
Authors
Dates
2017-06-21—Published
2016-07-28—Filed